Such impressive responses have led to changes in the ongoing therapeutic algorithm of advanced NSCLC, with a new first-line treatment option for patients with tumors positive for PD-L1 [4] and a second-line option after an initial CT regimen. Here, CD274 is linked to non-small cell lung carcinoma.